CD44v6与非小细胞肺癌的研究进展

doi:10.11904/j.issn.1002-3070.2016.02.017

Abstract

Abstract: CD44 is a transmembrane glycoprotein,which is a family of highly specific single chain membrane surface glycoproteins by a single gene.CD44 is mainly involved in the specific adhesion between cells and cells,cells and matrix.CD44v6 is a member of the CD44 family,and its correlation with metastasis and prognosis of non small cell lung cancer(NSCLC)has become a hot research topic in recent years.The current research progress of CD44v6 and NSCLC are reviewed in this paper.

Key words: CD44v6, Non-small cell lung cancer, Literature review

CLC Number:

R734.2

CHEN Minghui, CHEN Xijie, WANG Yan. Research progress of CD44v6 in non-small cell lung cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 172-175.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2016.02.017

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2016/V30/I2/172

References

1 Siegel R,Naishadham D,Jemal A.Cancer statistics,2013[J].CA Cancer J Clin,2013,63(1):11-30.
2 Haynes BF,Telen MJ,Hale LP,et al.CD44-a molecule involved in leukocyte adherence and T-cell activation[J].Immunology Today,1989,10(12):423-428.
3 Orian-Rousseau V,Sleeman J.CD44 is a multidomain signaling platform that integrates extracellular matrix cues with growth factor and cytokine signals[J].Adv Cancer Res,2014,123(2):231-54.
4 Orian-Rousseau V.CD44,a therapeutic target for metastasising tumours[J].European Journal of Cancer,2010,46(7):1271-1277.
5 Almond A.Hyaluronan[J].Cell Mol Life Sci,2007,64(13):1591-1596.
6 Bourguignon LYW,Spevak CC,Wong G,et al.Hyaluronan-CD44 interaction with protein kinase C promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21,leading to down-regulation of the tumor suppressor protein PDCD4,anti-apoptosis,and chemotherapy resistance in breast tumor cells[J].Journal of Biological Chemistry,2009,284(39):26533-26546.
7 Negi LM,Talegaonkar S,Jaggi M,et al.Role of CD44 in tumour progression and strategies for targeting[J].Journal of Drug Targeting,2012,20(7):561-573.
8 孙冰生,裴宝祥,王安雷,等.骨桥蛋白及其受体 CD44v 对肿瘤侵袭调控的研究进展[J].中国肺癌杂志,2015,18(11):714-717.
9 李轰,祝凯,魏朝霞,等.非小细胞肺癌 CD44 途径免疫逃逸机制初步探讨[J].齐鲁医学杂志,2010,25(3):202-204.
10 杨景伟,沈毅,魏煜程,等.CD44s 和 CD44v6 在肺癌组织中的表达及意义[J].山东医药,2007,46(36):51-52.
11 Situ D,Long H,Lin P,et al.Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma[J].J Cancer Res Clin Oncol,2010,136(8):1213-1219.
12 牛艳清.NSCLC中COX-2和CD44v6的表达与淋巴结转移关系[J].长治医学院学报,2014,28(3):178-180.
13 Su CY,Li YS,Han Y,et al.Correlation between expression of cell adhesion molecules CD44v6 and E-cadherin and lymphatic metastasis in non-small cell lung cancer[J].Asian Pac J Cancer Prev,2013,15(5):2221-2224.
14 Afify AM,Tate S,Durbin-Johnson B,et al.Expression of CD44s and CD44v6 in lung cancer and their correlation with prognostic factors[J].The International Journal of Biological Markers,2010,26(1):50-57.
15 Luo Z,Wu RR,Lv L,et al.Prognostic value of CD44 expression in non-small cell lung cancer:a systematic review[J].Int J Clin Exp Pathol,2014,7(7):3632-3646.
16 Hirata T,Fukuse T,Naiki H,et al.Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor[J].Cancer Research,1998,58(6):1108-1110.
17 Zhao S,He JL,Qiu ZX,et al.Prognostic value of CD44 variant exon 6 expression in non-small cell lung cancer:a meta-analysis.[J].Asian Pacific Journal of Cancer Prevention,2014,15(16):6761-6766.
18 Ramasami S,Kerr KM,Chapman AD,et al.Expression of CD44v6 but not E-cadherin or β-catenin influences prognosis in primary pulmonary adenocarcinoma[J].The Journal of Pathology,2000,192(4):427-432.
19 Ko YH,Won HS,Jeon EK,et al.Prognostic significance of CD44s expression in resected non-small cell lung cancer[J].Bmc Cancer,2011,11(1):1-9.
20 Jiang H,Zhao W,Shao W.Prognostic value of CD44 and CD44v6 expression in patients with non-small cell lung cancer:meta-analysis[J].Tumour Biol,2014,35(8):7383-7389.
21 Li R,Zhang C,Wang B.A study on the change of the serum levels of soluble sCD44v6 and the expression of CD44v6 in the tissues of gastric tumor[J].Hebei Med J,2006,28(5):355-358.
22 He Y,Zhang J,Wang SK,et al.Serum sCD44v6 and sE-cadherin levels in patients with esophageal squamous cell carcinoma[J].Zhejiang Da Xue Xue Bao,2012,41(3):305-309.
23 赵丽红,田建辉.非小细胞肺癌患者 sCD44v6 的检测意义[J].实用中西医结合临床,2006,6(5):11-12.
24 李炯,沈德义,沈敏祺.sCD44V6 检测对非小细胞肺癌的临床意义[J].肿瘤研究与临床,2005,17(1):21-22.
25 叶珩,钱科卿,岑玲.非小细胞肺癌患者血清 sCD44v6 检测的临床意义[J].现代肿瘤医学,2008,16(1):46-47.
26 张真,韩淑红,张小涛,等.非小细胞肺癌同步放化疗前后血清 CD44v6 表达水平及其临床意义[J].医学研究杂志,2013,42(7):112-114.

[1]	LU Juping, HU Jun, DENG Yongming, LIAO Shufang. Downregulation of FKBP4 inhibits the malignant progression of non-small cell lung cancer by blocking the PI3K/Akt/mTOR signaling pathway [J]. Journal of Practical Oncology, 2025, 39(3): 184-190.
[2]	LI Caizheng, ZHENG Jing, SU Qiaoli. Advance progress in immunotherapy for unresectable locally advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2025, 39(1): 67-72.
[3]	HAO Huiting, ZHAO Huijuan, XU Qiaohui. Expression and clinical significance of hypermethylated in cancer 1 in non-small cell lung cancer [J]. Journal of Practical Oncology, 2024, 38(5): 306-312.
[4]	XU Lingyan, LI Qianni, LI Jian, YAO Xuepei, LIU Meina. Analysis for the impact of the first hospitalization days on treatment quality in patients with non-small cell lung cancer [J]. Journal of Practical Oncology, 2024, 38(4): 221-226.
[5]	YAO Xuepei, BAI Shanqi, LIU Meina. Analysis of factors influencing treatment quality of non-small cell lung cancer based on causal diagram model [J]. Journal of Practical Oncology, 2024, 38(4): 227-234.
[6]	LI Jian, LI Qianni, XU Lingyan, YAO Xuepei, LIU Meina. Research on the causal effects of non-small cell lung cancer treatment process on in-hospital mortality based on double robust estimation method [J]. Journal of Practical Oncology, 2024, 38(4): 235-240.
[7]	CHENG Yongming, DONG Huanhuan, XU Hui. Hsa-let-7b-5p inhibits proliferation,migration and invasion in non-small cell lung cancer [J]. Journal of Practical Oncology, 2024, 38(3): 157-167.
[8]	ZHANG Xuan, LI Xin, ZHAO Kang. Relationship between serum inflammatory markers and prognosis of advanced non-small cell lung cancer patients treated with first-line immunosuppressants [J]. Journal of Practical Oncology, 2024, 38(1): 37-44.
[9]	MIAO Ling, ZHAO Zhihan, WANG Min. Levels and clinical significance of PA28γ and miR-7-5p in tumor tissues of patients with non-small cell lung cancer [J]. Journal of Practical Oncology, 2023, 37(4): 344-350.
[10]	CAO Yingyue, PANG Luyi, ZHANG Jian, JIN Shi. The role of cancer-associated fibroblasts in the progression of non-small cell lung cancer [J]. Journal of Practical Oncology, 2023, 37(4): 383-388.
[11]	CHEN Qi, HE Mingxv, JIA Keliang, MIAO Jianlong, HAN Liping. Research progress on the prognosis and treatment of non-small cell lung cancer with TP53-EGFR co-mutation [J]. Journal of Practical Oncology, 2023, 37(3): 262-266.
[12]	LONG Chaolian, LI Kun, LIU Zichen, ZHANG Nana, CHE Nanying. The correlation between the expression of programmed death ligand 1 in non-small cell lung cancer and clinical pathological features and common driver gene mutation [J]. Journal of Practical Oncology, 2023, 37(2): 117-122.
[13]	XU Zihan, YU Guohua, NIE Yuhui, SUN Mengmeng, FENG Hui, LIU Shuzhen. Predictive effect of peripheral blood markers on immune-related adverse reactions of advanced non-small cell lung cancer and their correlation with survival outcome [J]. Journal of Practical Oncology, 2022, 36(6): 544-550.
[14]	ZHU Kaibin, HE Changjun, CHEN Lantao, KONG Xianglong, ZHAO Su, XU Shidong. Tumor-associated macrophages promotes non-small cell lung cancer growth and tumor vascularization via PLGF/Flt-1 and TGF-β1 signal pathway [J]. Journal of Practical Oncology, 2022, 36(5): 391-397.
[15]	LIU Qianqian, SHANG Lihua. Research progress on the correlation between immune-related adverse reactions and efficacy of immunotherapy in advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(5): 463-467.

Research progress of CD44v6 in non-small cell lung cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments